<DOC>
	<DOCNO>NCT02182778</DOCNO>
	<brief_summary>To validate superiority Gemcitabine/Cisplatin/S-1 Gemcitabine/Cisplatin unresectable biliary tract cancer .</brief_summary>
	<brief_title>GEM/Cisplatin/S-1 v GEM/Cisplatin Biliary Tract Cancer</brief_title>
	<detailed_description>Gemcitabine/cisplatin combination therapy ( GC ) standard palliative chemotherapy patient advance biliary tract cancer ( BTC ) . Investigators evaluate efficacy safety gemcitabine/cisplatin/S-1 combination therapy ( GCS ) patient advance BTC observe promising efficacy . In randomized phase â…¢ study , investigator aim compare GCS GC patient advance BTC .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>S 1 ( combination )</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>1 . Patients cytologically histologically proved biliary tract cancer 2. age &gt; =20 year 3 . Performance Status ( PS ) 02 4 . No prior history chemotherapy radiotherapy . 5 . Adequate bone marrow function ( neutrophil count &gt; =1,500/mm3 , platelet count &gt; =100,000/mm3 ) , liver function ( total bilirubin &gt; =3 mg/dL AST/ALT &gt; =150 IU/L ) , renal function ( creatinine clearance &gt; =45 mL/min ) 6 . Adequate oral intake 7 . Provided write informed consent 1 . Patients interstitial pneumonia pulmonary fibrosis 2 . Patients uncontrollable diabetes mellitus , liver disease , angina pectoris new onset myocardial infarction within 3 month 3 . Patients severe active infection 4 . Patients moderate mark pleural effusion ascites necessitating drainage 5 . Patients history severe drug allergy 6 . Patients serious comorbid disease 7 . Patients pregnant lactating , intention get pregnant 8 . Patients mental disease 9 . Patients judge inappropriate entry study principle doctor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>